Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader

RSC Medicinal Chemistry(2025)10.1039/d5md00119fSource: DataRank Database

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader is a research paper published in RSC Medicinal Chemistry (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.68)OA: hybridTopics (9)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Dinesh Thummuri ORCID,Wanyi Hu,Sajid Khan ORCID,Yonghan He ORCID,Xuan Zhang ORCID

Live enrichment

PubMed:40510905 PMC:PMC12155403 OpenAlex:https://openalex.org/W4410664177

National Institutes of Health

Grant: R01CA241191

National Institutes of Health

Grant: R01CA260239

National Institutes of Health

Grant: 5R01CA260239-05

Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis

National Institutes of Health

Grant: 5R01CA241191-03

Inhibition of Bcl-xL by Targeted Degradation

FWCI

1.68

Citation Percentile

0.8%

Citation Trend

2026

hybridLicense: cc-by-nc

journalhttps://pubs.rsc.org/en/content/articlepdf/2025/md/d5md00119f

publisherhttps://pubs.rsc.org/en/content/articlepdf/2025/md/d5md00119f

publisherhttp://pubs.rsc.org/en/content/articlepdf/2025/MD/D5MD00119F

journalhttps://doi.org/10.1039/d5md00119f

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40510905

Fields of Study

Nerve injury and regenerationProtein Degradation and InhibitorsPARP inhibition in cancer therapy

Keywords

In vivoChemistryPharmacologyComputational biologyBiologyBiotechnology

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader

FAIR Checklist

Authors (10)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)